Need Help?

Predicting brain tumor recurrence: development and validation of a DNA-methylation based nomogram in meningioma

Our work is the first to demonstrate the transformative utility of integrating clinical and molecular factors for use beyond simple classification into the realm of individualized prognostication for any brain tumor. Using our developed and validated tools that are publicly available, clinicians will be able combine clinical and molecular factors to determine an individualized probability of recurrence for patients with meningiomas. This represents a major advance in the field of personalized medicine for neuro-oncology, and the use of this tool can help clinicians overcome one of the most challenging limitations we face when treating patients with meningiomas.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00010001687 Illumina 280
Publications Citations
DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management.
Neuro Oncol 21: 2019 901-910
113